Davis CB - Search Results

1

Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.

Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Benincosa LJ, et al. Among authors: davis cb. J Pharmacol Exp Ther. 2000 Feb;292(2):810-6. J Pharmacol Exp Ther. 2000. PMID: 10640322

2

Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.

Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. Chow FS, et al. Among authors: davis cb. Clin Pharmacol Ther. 2002 Apr;71(4):235-45. doi: 10.1067/mcp.2002.122276. Clin Pharmacol Ther. 2002. PMID: 11956506 Clinical Trial.

3

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.

Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC. Mould DR, et al. Among authors: davis cb. Clin Pharmacol Ther. 1999 Sep;66(3):246-57. doi: 10.1016/S0009-9236(99)70032-9. Clin Pharmacol Ther. 1999. PMID: 10511060 Clinical Trial.

4

Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. Zia-Amirhosseini P, et al. Among authors: davis cb. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7. J Pharmacol Exp Ther. 1999. PMID: 10565825

5

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.

Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK. Sharma A, et al. Among authors: davis cb. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. J Pharmacol Exp Ther. 2000. PMID: 10734150

6

Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice.

Hepburn TW, Hart TK, Horton VL, Sellers TS, Tobia LP, Urbanski JJ, Shi W, Davis CB. Hepburn TW, et al. Among authors: davis cb. J Pharmacol Exp Ther. 2001 Sep;298(3):886-93. J Pharmacol Exp Ther. 2001. PMID: 11504781

7

Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. Davis CB, et al. Drug Metab Dispos. 1995 Oct;23(10):1028-36. Drug Metab Dispos. 1995. PMID: 8654189

8

Disposition of metabolically radiolabeled CE9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4.

Davis CB, Garver EM, Kwok DC, Urbanski JJ. Davis CB, et al. Drug Metab Dispos. 1996 Sep;24(9):1032-7. Drug Metab Dispos. 1996. PMID: 8886616

9

Impact of erythrocyte Duffy antigen genetic polymorphism on the distribution of GroBeta-T, a novel human CXC chemokine.

Hepburn TW, Tobia LP, Shi W, McIntyre TA, Davis CB. Hepburn TW, et al. Among authors: davis cb. J Pharm Pharm Sci. 2007;10(4):486-95. doi: 10.18433/j33w2m. J Pharm Pharm Sci. 2007. PMID: 18396564 Free article.

10

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. Everitt DE, et al. Among authors: davis cb. J Infect Dis. 1996 Sep;174(3):463-9. doi: 10.1093/infdis/174.3.463. J Infect Dis. 1996. PMID: 8769601 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters